DNDi addresses 'alarming lack' of R&D for neglected diseases

In a Center for Global Health R&D Policy Assessment blog post, the third part of the center's Product Development Partnership (PDP) mini-series, "Bernard Pecoul from the Drugs for Neglected Diseases initiative (DNDi) discusses their experience with partnerships to develop treatments for neglected diseases." Pecoul writes, "DNDi exists because of the alarming lack of R&D for the most neglected diseases in the world, which affect the poorest people but do not represent lucrative 'market potential' for the pharmaceutical industry. Our objective at DNDi is to address this terrible gap between neglected patient needs and R&D and to bridge the innovation-to-access divide" (8/16).